{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:37:19Z","timestamp":1791434239346,"version":"4.3.3"},"reference-count":73,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel\u2013Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC. However, limited data about their efficacy in BM is available, and no systematic comparisons have been performed. We developed mouse models of bone and lung ccRCC tumors and compared their anticancer efficacy, impact on mouse survival, and mechanisms of action, including effects on tumor cells and both immune and nonimmune (blood vessels and osteoclasts) bone stromal components. This approach elucidates the efficacy of TKIs in ccRCC bone tumors to support rational interrogation and development of therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>TKIs showed different efficacy in synchronous bone and lung metastases and did not eradicate tumors as single agents but induced extensive reprogramming of the BM microenvironment. This resulted in a significant decrease in neoangiogenic blood vessels, bone remodeling, and immune cell infiltration (including CD8 T cells) with altered spatial distribution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0304","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T09:16:48Z","timestamp":1725873408000},"page":"2621-2637","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-082X","authenticated-orcid":false,"given":"Stefan","family":"Maksimovic","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0366-0837","authenticated-orcid":false,"given":"Nina C.","family":"Boscolo","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7850-4925","authenticated-orcid":false,"given":"Ludovica","family":"La Posta","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-2466","authenticated-orcid":false,"given":"Sergio","family":"Barrios","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"},{"name":"Department of Bioengineering, Rice University, Houston, Texas. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7960-8614","authenticated-orcid":false,"given":"Mohammad Jad","family":"Moussa","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0332-2385","authenticated-orcid":false,"given":"Emanuela","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6318-1290","authenticated-orcid":false,"given":"Pedro I.","family":"Pesquera","sequence":"additional","affiliation":[{"name":"Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-8489","authenticated-orcid":false,"given":"Wenjiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-1207","authenticated-orcid":false,"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-744X","authenticated-orcid":false,"given":"Javier A.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7252-1126","authenticated-orcid":false,"given":"Akshay","family":"Basi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-9074","authenticated-orcid":false,"given":"Jared K.","family":"Burks","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-6532","authenticated-orcid":false,"given":"Christopher","family":"Alvarez-Breckenridge","sequence":"additional","affiliation":[{"name":"Division of Surgery, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-4472","authenticated-orcid":false,"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-5418","authenticated-orcid":false,"given":"Eleonora","family":"Dondossola","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1"},{"name":"Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2025040317284869600_bib1","first-page":"133","article-title":"Genetics and epigenetics of renal cell cancer","volume":"1785","author":"Baldewijns","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"2025040317284869600_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"key":"2025040317284869600_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025040317284869600_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amsu.2018.01.002","article-title":"Skeletal metastasis in renal cell carcinoma: a review","volume":"27","author":"Umer","year":"2018","journal-title":"Ann Med Surg (Lond)"},{"key":"2025040317284869600_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"2025040317284869600_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10585-011-9379-7","article-title":"Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis","volume":"28","author":"Yuasa","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"2025040317284869600_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21037\/aoj-20-97","article-title":"Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease","volume":"7","author":"DiCaprio","year":"2022","journal-title":"Ann Jt"},{"key":"2025040317284869600_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"Mckay","year":"2014","journal-title":"Eur Urol"},{"key":"2025040317284869600_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"2025040317284869600_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13046-018-0952-7","article-title":"Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity","volume":"37","author":"Trotta","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"2025040317284869600_bib11","first-page":"4233","article-title":"Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis","volume":"54","author":"Takahashi","year":"1994","journal-title":"Cancer Res"},{"key":"2025040317284869600_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fped.2018.00016","article-title":"Renal cell carcinoma in von Hippel-Lindau disease-from tumor genetics to novel therapeutic strategies","volume":"6","author":"Kim","year":"2018","journal-title":"Front Pediatr"},{"key":"2025040317284869600_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025040317284869600_bib14","first-page":"E509","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"19","author":"Motzer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025040317284869600_bib15","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"2025040317284869600_bib16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025040317284869600_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025040317284869600_bib18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"2025040317284869600_bib19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025040317284869600_bib20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025040317284869600_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025040317284869600_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/15384047.2016.1219816","article-title":"Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation","volume":"18","author":"Zhao","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"2025040317284869600_bib23","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"2025040317284869600_bib24","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.3390\/ijms21228529","article-title":"Tyrosine kinase receptors in oncology","volume":"21","author":"Esteban-Villarrubia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025040317284869600_bib25","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/2159-8290.CD-21-0925","article-title":"A targetable myeloid inflammatory state governs disease recurrence in clear-cell renal cell carcinoma","volume":"12","author":"Rappold","year":"2022","journal-title":"Cancer Discov"},{"key":"2025040317284869600_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"2025040317284869600_bib27","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41388-020-1234-3","article-title":"Modeling clear cell renal cell carcinoma and therapeutic implications","volume":"39","author":"Wolf","year":"2020","journal-title":"Oncogene"},{"key":"2025040317284869600_bib28","doi-asserted-by":"crossref","first-page":"29032","DOI":"10.1038\/srep29032","article-title":"CRISPR-mediated VHL knockout generates an improved model for metastatic renal cell carcinoma","volume":"6","author":"Schokrpur","year":"2016","journal-title":"Sci Rep"},{"key":"2025040317284869600_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.21873\/anticanres.14140","article-title":"Hypoxia inducible factor-1\u03b1 inhibition in von Hippel lindau-mutant malignant pleural mesothelioma cells","volume":"40","author":"Shukuya","year":"2020","journal-title":"Anticancer Res"},{"key":"2025040317284869600_bib30","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1158\/0008-5472.CAN-11-0757","article-title":"VHL gene mutations and their effects on hypoxia inducible factor HIF\u03b1: identification of potential driver and passenger mutations","volume":"71","author":"Rechsteiner","year":"2011","journal-title":"Cancer Res"},{"key":"2025040317284869600_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1535-7163.MCT-19-0174","article-title":"Cabozantinib reverses renal cell carcinoma-mediated osteoblast inhibition in three-dimensional coculture in vitro and reduces bone osteolysis in vivo","volume":"19","author":"Pan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025040317284869600_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1359\/jbmr.061005","article-title":"TGF-\u0392 promotes the establishment of renal cell carcinoma bone metastasis","volume":"22","author":"Kominsky","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2025040317284869600_bib33","first-page":"262743","article-title":"Enhancing Radium 223 treatment efficacy by anti-beta 1 integrin targeting","volume":"121","author":"Paindelli","year":"2021","journal-title":"J Nucl Med"},{"key":"2025040317284869600_bib34","doi-asserted-by":"crossref","first-page":"e2103623118","DOI":"10.1073\/pnas.2103623118","article-title":"Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer","volume":"118","author":"Bello","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317284869600_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jnci\/djz007","article-title":"Radium 223-mediated zonal cytotoxicity of prostate cancer in bone","volume":"111","author":"Dondossola","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025040317284869600_bib36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat Med"},{"key":"2025040317284869600_bib37","doi-asserted-by":"crossref","first-page":"100399","DOI":"10.1016\/j.jbo.2021.100399","article-title":"All bone metastases are not created equal: revisiting treatment resistance in renal cell carcinoma","volume":"31","author":"Brozovich","year":"2021","journal-title":"J Bone Oncol"},{"key":"2025040317284869600_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025040317284869600_bib39","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025040317284869600_bib40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/molecules23040747","article-title":"Design, synthesis, and biological evaluation of axitinib derivatives","volume":"23","author":"Wei","year":"2018","journal-title":"Molecules"},{"key":"2025040317284869600_bib41","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/ijc.25611","article-title":"The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts","volume":"128","author":"R\u00f6ssler","year":"2011","journal-title":"Int J Cancer"},{"key":"2025040317284869600_bib42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.biopha.2014.07.002","article-title":"Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation","volume":"68","author":"Yuan","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"2025040317284869600_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025040317284869600_bib44","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2025040317284869600_bib45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7150\/jca.14604","article-title":"MET inhibition in clear cell renal cell carcinoma","volume":"7","author":"Xie","year":"2016","journal-title":"J Cancer"},{"key":"2025040317284869600_bib46","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025040317284869600_bib47","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"2025040317284869600_bib48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/1471-2407-11-309","article-title":"E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion","volume":"11","author":"Glen","year":"2011","journal-title":"BMC Cancer"},{"key":"2025040317284869600_bib49","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.3892\/mmr.2017.7456","article-title":"A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma","volume":"16","author":"Li","year":"2017","journal-title":"Mol Med Rep"},{"key":"2025040317284869600_bib50","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.21873\/anticanres.13802","article-title":"Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo","volume":"39","author":"Ogasawara","year":"2019","journal-title":"Anticancer Res"},{"key":"2025040317284869600_bib51","doi-asserted-by":"crossref","first-page":"11361","DOI":"10.1038\/s41598-023-37857-9","article-title":"Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model","volume":"13","author":"Watanabe","year":"2023","journal-title":"Sci Rep"},{"key":"2025040317284869600_bib52","doi-asserted-by":"crossref","first-page":"100659","DOI":"10.1016\/j.xcrm.2022.100659","article-title":"Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma","volume":"3","author":"Hagege","year":"2022","journal-title":"Cell Rep Med"},{"key":"2025040317284869600_bib53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41419-022-05171-3","article-title":"Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025040317284869600_bib54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"2025040317284869600_bib55","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"2025040317284869600_bib56","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/modpathol.2009.88","article-title":"Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study","volume":"22","author":"Tong","year":"2009","journal-title":"Mod Pathol"},{"key":"2025040317284869600_bib57","doi-asserted-by":"crossref","first-page":"15766","DOI":"10.18632\/oncotarget.24607","article-title":"Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma","volume":"9","author":"Frees","year":"2018","journal-title":"Oncotarget"},{"key":"2025040317284869600_bib58","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s43018-023-00584-1","article-title":"Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer","volume":"4","author":"Perelli","year":"2023","journal-title":"Nat Cancer"},{"key":"2025040317284869600_bib59","doi-asserted-by":"crossref","first-page":"100745","DOI":"10.1016\/j.tranon.2020.100745","article-title":"Choosing the right animal model for renal cancer Research","volume":"13","author":"Sobczuk","year":"2020","journal-title":"Transl Oncol"},{"key":"2025040317284869600_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.urolonc.2019.10.012","article-title":"Animal models of spontaneous renal carcinoma: a possible rebirth?","volume":"38","author":"Mazzola","year":"2020","journal-title":"Urol Oncol"},{"key":"2025040317284869600_bib61","doi-asserted-by":"crossref","first-page":"bio058566","DOI":"10.1242\/bio.058566","article-title":"Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model","volume":"10","author":"Park","year":"2021","journal-title":"Biol Open"},{"key":"2025040317284869600_bib62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-009-0015-5","article-title":"VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy","volume":"11","author":"Cowey","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"2025040317284869600_bib63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1078-0432.CCR-15-0235","article-title":"Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer","volume":"22","author":"Varkaris","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025040317284869600_bib64","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025040317284869600_bib65","first-page":"242","article-title":"Lenvatinib","volume":"40","year":"2017","journal-title":"Aust Prescr"},{"key":"2025040317284869600_bib66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.18773\/austprescr.2018.024","article-title":"Cabozantinib for renal cell carcinoma","volume":"41","year":"2018","journal-title":"Aust Prescr"},{"key":"2025040317284869600_bib67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/cancers14030644","article-title":"Combination of anti-angiogenics and checkpoint inhibitors for renal cell carcinoma: is the whole greater than the sum of its parts?","volume":"14","author":"Jonasch","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025040317284869600_bib68","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"2025040317284869600_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"\u015eenbabao\u011flu","year":"2016","journal-title":"Genome Biol"},{"key":"2025040317284869600_bib70","first-page":"1016","article-title":"VEGF inhibitors in renal cell carcinoma","volume":"14","author":"Vachhani","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025040317284869600_bib71","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"2025040317284869600_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","article-title":"Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology","volume":"45","author":"Nifos\u00ec","year":"2019","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"2025040317284869600_bib73","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? subgroup analysis of the METEOR trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0304\/3494360\/crc-24-0304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2621\/3505242\/crc-24-0304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2621\/3505242\/crc-24-0304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:53:48Z","timestamp":1743731628000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/10\/2621\/748869\/Antiangiogenic-Tyrosine-Kinase-Inhibitors-have"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0304","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7484474","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27187289","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187310","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727354","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187277","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727366","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187265","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727396","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727372","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727384","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727390","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187304","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187316","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187271","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187295","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187283","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187268","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187313","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727369","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187301","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187286","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727357","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187274","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727387","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187298","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727375","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187319","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727381","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727393","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187307","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187292","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27187280","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}